Blood Cancer Talks Episode 51. Venetoclax in AML with Dr. Andrew Wei
70 snips
Sep 27, 2024 Dr. Andrew Wei, a leading expert in acute myeloid leukemia from the Peter McCallum Cancer Center, discusses the innovative use of venetoclax in treating AML. He highlights groundbreaking clinical trials that have transformed treatment pathways, particularly for older patients. Innovative therapies like venetoclax combined with hypomethylating agents are explored, along with ongoing resistance challenges and the role of genetic mutations in personalized treatment. The conversation also touches on the implications of minimal residual disease negativity in enhancing patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Bone Marrow Assessment Timing
- Assess bone marrow on day 21 for inpatients to confirm blast clearance and adjust treatment.
- For outpatients, consider bone marrow assessment based on individual risk factors.
Optimal Dosing Strategy
- Prioritize optimal dosing over maximizing dose to avoid progenitor burnout.
- Allow for bone marrow recovery between cycles, often extending beyond four weeks.
Tumor Lysis Syndrome Risk
- The lower TLS risk in AML versus CLL is partly due to combination therapy and proactive management.
- Specific mutations like IDH2 and high blast counts increase TLS susceptibility.